Dravet Syndrome Treatment Market By Type of Drugs (Topiramate, Levetiracetam, Zonisamide, Valproic Acid, Clobazam, Clonzepam, Stiripentol, Cannabidiol) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Dravet syndrome treatment accounted for a market value of US$ 209.2 million in 2018 and is expected to grow at an 11.7% CAGR from 2019 to 2027. The current treatment options for Dravet syndrome focus on the symptomatic relief associated with epileptic seizures. However, recent drug approvals for Dravet syndrome treatment have increased the overall market size and attracted the attention of major pharmaceutical companies.

In June 2018, Epidiolex (Cannabidiol) from GW Pharmaceuticals was approved by the USFDA specifically for Dravet syndrome. Epidiolex was followed by Fintepla (earlier ZX008), which is awaiting approval in the United States and Europe, and boosted Zogenix shares by 20.5% in March 2019. Thus, overall target-specific drugs are entering the Dravet syndrome treatment horizon, with their market growth expected to spurt from 2019 to 2027.

Market Synopsis

Stiripentol and cannabidiol will assist in the significant growth of the Dravet syndrome treatment market throughout the forecast period.

The U.S. Food and Drug Administration (FDA) approved stiripentol (Diacomit) in August 2018 to treat seizures associated with Dravet syndrome. Stiripentol's market share is growing at a significant rate post-2018 due to its higher efficiency, safety, and prolonged relief from seizures.

In addition to that, a cannabidiol brand named Epidiolex, manufactured by GW Research Ltd., was approved in June 2018. Cannabidiol is the first FDA-approved drug that contains a purified drug substance derived from marijuana. Thus, the overall environment of the Dravet syndrome treatment market is growing significantly due to a strong drug pipeline and recently approved drugs.

North America dominated the overall global market, especially due to recent drug approvals and developed diagnostic technology.

In 2017, North America dominated the market and was expected to maintain its dominance throughout the forecast period due to key market drivers such as rising awareness related to neurological disorders, increasing demand for target-specific drugs to treat Dravet syndrome, and high accessibility and adaptability for recently launched drugs.

During the forecast period from 2019 to 2027, Asia-Pacific is expected to grow significantly throughout the forecast period due to increasing awareness related to Dravet syndrome coupled with the developing diagnostic technologies in the neurological disease area.

Periods of History and Forecast

The Dravet syndrome treatment market was analyzed considering current market trends for the base year of 2018,and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report comprises quantitative and qualitative data associated with the Dravet syndrome treatment market, along with key market dynamics covering market opportunities, drivers, and restraints that possess their own positive and negative effects. An elaborative analysis of market drivers, challenges, and opportunities based on country-level and regional segmentation is covered in the current scope of the report.

This report comprises detailed data related to the global Dravet syndrome treatment market, segmented by such factors as drug type and geography. The report also includes a competitive analysis of the major companies present in the Dravet syndrome treatment market, including detailed data related to the competitive landscape of the market and the recent strategies and products entering the market.

The key market players involved in the Dravet syndrome treatment industry were studied based on financial data, product portfolios, current press releases, and key market strategies. This report also covers attractive investment propositions analyzed based on an exclusive geographical PESTEL analysis. Major companies included in the report are GW Pharmaceuticals Plc., Ovid Therapeutics, PTC Therapeutics, Inc., Epygenix Therapeutics, Inc., Zogenix, Inc., Takeda Pharmaceutical Company Ltd., Biocodex S.A., OPKO Health Inc., and Biscayne Neurotherapeutics, Inc., among others.

Key questions are answered in this report.

  • Which is the most preferred drug to treat Dravet syndrome and why?
  • What are the recent market strategies followed by the key companies and the competitive landscape of the Dravet syndrome treatment market?
  • Which are the current and future major geographical markets (regions and countries) for Dravet syndrome treatment?
  • Which is the largest and fastest-growing Dravet syndrome treatment segment globally?
  • What are the drivers, restraints, and opportunities in the Dravet syndrome treatment market?

Frequently Asked Question:

The market for Dravet Syndrome Treatment Market is expected to reach USD$ 209.2 Mn in 2027.

The Dravet Syndrome Treatment Market is expected to see significant CAGR growth over the coming years, at 11.7%.

The report is forecasted from 2019 -2027.

The base year of this report is 2018.

Denso Corporation, Delphi Technologies, Magna Infotech, Panasonic Corporation, General Electric, Qualcomm, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  May 2019
Category:  Pharmaceuticals
Report ID:   59709
Report Format:   PDF
Pages:   120
Rating:    4.4 (49)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support